ReviewAdvances in experimental medicine and biology
Advanced Injectable Alternatives for Osteoarthritis.
Review in Advances in experimental medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Innate immune pathway activated mesenchymal stromal cells improve function and histologic outcomes in a rodent osteoarthritis model.Frontiers in bioengineering and biotechnology · 2025Article
- Erythrocyte removal from bone marrow aspirate concentrate improves efficacy as intra-articular cellular therapy in a rodent osteoarthritis model.Annals of translational medicine · 2023Article
- Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems.Advanced therapeutics · 2021Article
- miR-17-5p and miR-19b-3p prevent osteoarthritis progression by targeting EZH2.Experimental and therapeutic medicine · 2020Article
- p-Coumaric Acid Attenuates IL-1β-Induced Inflammatory Responses and Cellular Senescence in Rat Chondrocytes.Inflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a common form of arthritis, which is characterized by progressive degradation of joint cartilage resulting in pain, joint stiffness, deformity and disability that is also recently related to an increased incidence of mortality. Inhibition of the extracellular matrix (ECM) production by chondrocytes and accumulation of catabolic mediators associated with matrix degradation are the cause of OA. Nonsurgical treatments for OA can be characterised as symptom-modifying or disease-modifying approaches. It's estimated that 10% of the world population older than 60 years demonstrated symptoms of OA (Messier SP, Callahan LF, Beavers DP et al., BMC Musculoskelet Disord 18(1):91, 2017). A virtue of chondrocytes has a limited proliferation capability; nonsurgical OA therapies mostly include native cartilage extracellular component injections like hyaluronic acid, anti-inflammatory effected autologous cell implantations, platelet rich plasma injections and medicals like corticosteroids. Stem cells are searched to cure OA recently. Also nowadays we can develop injectable release systems, biocompatible hydrogels and micro/nano sized carriers to make these medicals more effective. In this review we cover injectable alternatives to modify the natural course of OA that gives a window for patients between conventional treatment methods and joint replacement surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.